PIMG
VRDN icon

Patriot Investment Management Group’s Viridian Therapeutics VRDN Stock Holding History

Patriot Investment Management Group’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-33
Closed -$555 – 634
2020
Q2 		$555 Buy
+33
New +$375 ﹤0.01% 682

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AVA
Atlas Venture Advisors Boston, Massachusetts $122M AUM 26.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Patriot Investment Management Group's VRDN Position: Q3 2020 in Review

Patriot Investment Management Group sold out of Viridian Therapeutics (VRDN) in Q3 2020, closing a stake of 33 shares — an estimated $555 sold.

Patriot Investment Management Group first reported a position in VRDN in Q2 2020 and held it in 1 quarter. The position peaked at $555 in Q2 2020. 26 funds tracked by Wall St. Rank hold VRDN as of Q3 2020.

  • Patriot Investment Management Group reported no remaining Viridian Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Patriot Investment Management Group sold 33 Viridian Therapeutics shares in Q3 2020, an estimated $555.
  • Patriot Investment Management Group first reported a position in Viridian Therapeutics in Q2 2020 and held it in 1 quarter.
  • Patriot Investment Management Group's Viridian Therapeutics position peaked at $555 in Q2 2020.
  • 26 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q3 2020.

Based on Patriot Investment Management Group's 13F filing for Q3 2020, filed 23 Oct 2020.